A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. - Wikidata - wikimedia - TriplyDB

A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.

A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.

http://www.wikidata.org/entity/Q33769618

about

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus HOXB13 promotes ovarian cancer progression Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models.Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism.Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer A mouse model for the molecular characterization of brca1-associated ovarian carcinoma Minireview: animal models and mechanisms of ovarian cancer development.K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.Rethinking ovarian cancer: recommendations for improving outcomes.Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo Modeling resistance to pathway-targeted therapy in ovarian cancer Alternative signaling pathways: when, where and why?Tumorigenesis and peritoneal colonization from fallopian tube epithelium.The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer PTEN, more than the AKT pathway.Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer.Radiation-induced EGFR-signaling and control of DNA-damage repair.Models of ovarian cancer metastasis: Murine models Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells Epithelial ovarian cancer experimental models.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Exploiting p70 S6 kinase as a target for ovarian cancer.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.Identification of LMX1B as a novel oncogene in human ovarian cancer.Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models.Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents.AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture.MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload.Genetically engineered mouse models of ovarian cancer and their utility in drug discovery.A polymorphism at miRNA-122-binding site in the IL-1α 3'UTR is associated with risk of epithelial ovarian cancer.

P2860

Q24306696-A86D83C0-5022-4CF6-882C-6D5FECFE2783 Q24600932-15165412-5C16-4FCE-8309-AF84C6444948 Q24675458-5E056773-E5CC-47B9-8E67-62F38D42EC8F Q27307193-60E94784-B0E3-456F-8262-3CB369813F56 Q27851755-392DE910-8781-4B7D-B8F0-DF80AE866983 Q28486318-BCAF67F5-0BBA-487D-BC7D-E5D3BFF5DC66 Q33533301-8383CC4E-9D38-41D7-9B92-01323417A827 Q33994590-5BEA4A7A-515D-4C53-90D0-0B91E20B8C62 Q34134454-6DB2451E-BC62-4D25-B76B-A8546DC5E5F0 Q34229795-F0BD2857-151F-49A0-9796-12D40E3187F5 Q34490603-AB4264BA-420D-47B3-858E-38504782BFA5 Q35067274-650D3AFD-0234-4842-880C-CA3B46F3E1D7 Q35631181-7A948712-CF24-4135-8DD3-D7B4FC1D7669 Q35646878-1A303E23-CD29-4B85-A19F-A55CAABDE1E6 Q35872732-3A2C1BB8-DF9E-4400-AFAF-FB0853D6179F Q35992132-ECBAE0C8-CCD3-4E2A-B873-5E53EF8B7393 Q36050883-281D649B-8D9D-48DC-B5B4-D914A7F8FAC9 Q36100451-CA8BF6BD-2B0B-451C-B8CA-DC57B74D225D Q36170527-26B64E43-B93B-4F56-B15D-FC88662A22BC Q36272217-9FBE8BD1-0F9D-4C03-B588-F59B162AC60A Q36299733-841DEE97-2641-4399-84B3-DCFB0E6F2E00 Q36541067-0C87CB06-7C17-4BB3-A4C4-99382B665489 Q36625238-7500CFE8-0B54-47E2-AA3F-50D12DA3DB52 Q36753139-9C497E80-8A0A-44A7-9E25-71C4450482BC Q37015667-4CB9CA63-4137-4285-98D0-19F12D7B90A0 Q37024025-4BD5C8F6-DF68-4659-B0EE-06D9F93F8FB5 Q37143526-56B303DE-FC20-4B6B-A191-9D69BFA6F06E Q37301601-A1A865F5-15B7-4253-B514-F78BADFA4AE3 Q37708938-8A6FF093-EF0B-453B-BE4E-981C1F2EE4A1 Q37795414-A7C30F58-35CC-4B88-A980-9DECCEF56A39 Q38007998-6A195142-9544-4691-B290-79CFB6343CED Q38869420-F2FCCDBD-4713-4C03-AD88-B447D7369529 Q39093097-33069723-C31D-497B-9D4E-AAAE632C502E Q39658817-46CCC515-6DE8-4E70-8F3B-79D3F37833FA Q39845438-50443BE4-CA02-4A65-BC8C-800AC9833E78 Q41284390-ECB7741D-DC0C-4B4B-BB20-E62D027F26D1 Q49379816-2B639528-2E51-4636-9DEE-13DA198F3AC0 Q53309853-BA9ACB69-3918-4861-B501-63E7AC66C8A6 Q54192639-358C66A7-5A18-483B-A625-6C4E2629F67D

P2860

A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.

http://www.wikidata.org/entity/Q33769618

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A genetically defined mouse ov ...... therapy and tumor resistance.

@ast

A genetically defined mouse ov ...... therapy and tumor resistance.

@en

type

label

A genetically defined mouse ov ...... therapy and tumor resistance.

@ast

A genetically defined mouse ov ...... therapy and tumor resistance.

@en

prefLabel

A genetically defined mouse ov ...... therapy and tumor resistance.

@ast

A genetically defined mouse ov ...... therapy and tumor resistance.

@en

P1433

Q33769618-55ABEC72-52E3-479B-93DD-A041E9AE7074

P1476

Q33769618-7B2E2AE4-969C-44E0-B807-3F446D967186

P2093

Q33769618-90CB7D14-A8FF-4135-825D-08B45AE7D764

Q33769618-E2488382-54D2-4BE2-A607-9610BF50830F

P2860

Q33769618-00833DF7-644A-456D-B031-5AF75E4434D2

Q33769618-06993427-2A22-4DD6-BBB7-A8577F4FEC26

Q33769618-070B7DC1-23A9-49E0-83CD-1DEAA2D4EF6D

Q33769618-147D4C4F-53DD-4F36-817F-1F870DE398DC

Q33769618-2D65DA6A-6C92-45FF-9405-08224B2EB87E

Q33769618-3DFBC76C-F178-4D30-83BD-9EDB2EE4DDD8

Q33769618-5E0017DF-28B2-4B01-B01A-1F5B059728E6

Q33769618-5F9D513B-F954-4CEF-AE52-E69B2DF23F04

Q33769618-61023FD7-F3FA-4726-91EB-E3C066F97C64

Q33769618-6B419A22-E6AC-4907-8DC9-4F49748796AD

P304

Q33769618-E3D3084E-73D4-4024-A4CD-C750FD9CE560

P31

Q33769618-7536C785-F35D-40A1-96EF-23B78E7AB4DC

P356

Q33769618-7AB3A840-C4AC-4B9A-8E9B-5B88A9148D9C

P407

Q33769618-1C40E858-2125-4F18-A49F-DD1F55EB98FC

P433

Q33769618-F6A362A0-62AB-436E-8A14-4BA6635D3CBE

P478

Q33769618-008B1941-6D8F-4981-AF3B-69D0AB6C73AC

P577

Q33769618-617E0C8C-1CD1-4652-B3F6-41EABE935374

P5875

Q33769618-8ED1C8F1-C2ED-4BD7-B1D2-E40A9502AA26

P698

Q33769618-0ABD6C6E-EA85-43F7-AF2E-4C6549D62051

P932

Q33769618-B6DD9148-FBE3-445E-8C04-4112292D6A48

P356

PNAS.0502256102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A genetically defined mouse ov ...... therapy and tumor resistance.

@en

P2093

Deyin Xing

http://www.w3.org/2001/XMLSchema#string

Sandra Orsulic

http://www.w3.org/2001/XMLSchema#string

P2860

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Targeting RAS signalling pathways in cancer therapy

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

Transformation of mammalian cells by constitutively active MAP kinase kinase

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Ovarian cancer: epidemiology, biology, and prognostic factors.

P304

6936-6941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0502256102

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7876844

http://www.w3.org/2001/XMLSchema#string

P698

15860581

http://www.w3.org/2001/XMLSchema#string

P932

1087513

http://www.w3.org/2001/XMLSchema#string